Aptose Biosciences Inc.
APTO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.03 | -0.00 | 0.08 |
| FCF Yield | 0.00% | 49.77% | -41.73% | -21.31% |
| EV / EBITDA | 0.00 | 0.00 | -2.05 | 1.77 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | -268.88% | 368.95% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | – | -0.40 | 0.50 | 5.09 |
| Growth | ||||
| Revenue 3-Year CAGR | 767,895.01% | 767,895.01% | 767,895.01% | 767,895.01% |
| Free Cash Flow Growth | -100.00% | 200.00% | 65.34% | 22.27% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -0.80 | 0.19 |
| Interest Coverage | 0.00 | 0.00 | -65.01 | 116.28 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -499.89 |